A collaborative group of Cedars-Sinai investigators suggest artificial intelligence can accurately assess volume, density of heart fat-both of which are linked to cardiovascular risk
/PRNewswire/ Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced the closing of its $4.9M preferred Series A1.
/PRNewswire/ Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced today that it has been awarded a Phase II Small.